You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MET Amplified NSCLC

Showing 1 - 25 of 5,189
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • Seoul, Gangnam-gu, Korea, Republic of
    Samsung Medical Center
Oct 27, 2023

NSCLC Trial in Worldwide (Osimertinib + Savolitinib, Savolitinib + Placebo)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Osimertinib + Savolitinib
  • Savolitinib + Placebo
  • Duarte, California
  • +20 more
Dec 2, 2022

NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • HS-10241+ Almonertinib
  • Pemetrexed + Cisplatin /Carboplatin
  • (no location specified)
Oct 29, 2023

Stomach Cancer, Adenocarcinoma Trial in Seoul (Durvalumab, Savolitinib)

Recruiting
  • Stomach Cancer, Adenocarcinoma
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jan 10, 2023

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University
Sep 19, 2023

Gastric Cancer, Gastroesophageal-junction Cancer Trial in Gyeonggi-do (Tepotinib plus paclitaxel)

Recruiting
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • Tepotinib plus paclitaxel
  • Gyeonggi-do, Korea, Republic of
    Hallym University Medical Center
Jun 29, 2022

NSCLC Trial in Worldwide (INC280, Gefitinib)

Completed
Has Results
  • Non-small Cell Lung Cancer
  • Woolloongabba, Queensland, Australia
  • +30 more
Mar 12, 2021

NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Department of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023

Non Small Cell Lung Cancer Trial in Worldwide (Telisotuzumab Vedotin)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • Clayton, Victoria, Australia
  • +54 more
Aug 23, 2022

NSCLC Trial in Pittsburgh (Capmatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jan 9, 2023

Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain

Completed
  • Metastatic Non-Small Cell Lung Cancer
  • East Hanover, New Jersey
    18 Novartis Investigative Sites in the US
Dec 29, 2022

NSCLC Trial in Houston (Amivantamab, Tepotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

NSCLC Trial in Guangzhou (PLB1001)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Aug 15, 2023

NSCLC Trial in Worldwide (Tepotinib, Osimertinib)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Yuma, Arizona
  • +178 more
Dec 19, 2022

Advanced Cancer, Non Small Cell Lung Cancer Trial (Tepotinib, Pembrolizumab)

Not yet recruiting
  • Advanced Cancer
  • Non Small Cell Lung Cancer
  • (no location specified)
Mar 28, 2023

Lung Cancer Trial (Savolitinib, Durvalumab)

Recruiting
  • Lung Cancer
  • Beijing, China
  • +2 more
Jan 11, 2023

Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

Recruiting
  • Non-Small Cell Lung Carcinoma
  • Capmatinib 150 mg
  • Capmatinib 200 mg
  • Guwahati, Assam, India
  • +7 more
Dec 19, 2022

NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • +4 more
  • (no location specified)
Oct 17, 2023

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

Malignant Non-small Cell Tumor of Lung Stage IV Trial in Boston (Capmatinib (INC280))

Completed
Has Results
  • Malignant Non-small Cell Neoplasm of Lung Stage IV
  • Capmatinib (INC280)
  • Boston, Massachusetts
    Massachusetts General Hospital
Mar 11, 2022

NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • Toripalimab
  • +3 more
  • Guanzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, drug, biological)

Not yet recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Nov 30, 2022

Esophagogastric Cancer Trial in United States (Amivantamab)

Recruiting
  • Esophagogastric Cancer
  • Boston, Massachusetts
  • +7 more
Oct 24, 2022

Advanced NSCLC With MET Mutations Trial in United States (Tepotinib)

Recruiting
  • Advanced Non-Small Cell Lung Cancer With MET Mutations
  • Aurora, Colorado
  • +3 more
Jun 27, 2022

NSCLC Trial in United States (capmatinib)

Recruiting
  • Non-small Cell Lung Cancer
  • La Jolla, California
  • +7 more
Oct 5, 2022